CAMP (CAMP4 Therapeutics Corporation Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by CAMP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-05 | Josh Mandel-Brehm | Chief Executive Officer | Buy | — | — |
| 2026-08-05 | Richard A Young | Director | Buy | — | — |
| 2026-08-05 | Andrew J. Schwab | Director | A | — | — |
| 2026-08-05 | 5AM Ventures VII, L.P. | 10%+ Owner | Buy | — | — |
| 2026-08-05 | Kelly Gold | Chief Financial Officer | Buy | — | — |
| 2026-08-05 | Yuri Maricich | Chief Medical Officer | Buy | — | — |
| 2026-06-12 | Andrew J. Schwab | Director | A | — | — |
| 2026-06-12 | Amir Nashat | Director | A | — | — |
| 2026-06-12 | Richard A Young | Director | A | — | — |
| 2026-06-12 | DOUGLAS E WILLIAMS | Director | A | — | — |
| 2026-06-12 | Steven H Holtzman | Director | A | — | — |
| 2026-06-12 | Murray Stewart | Director | A | — | — |
| 2026-04-03 | Kelly Gold | Chief Financial Officer | A | — | — |
| 2026-04-03 | Josh Mandel-Brehm | Chief Executive Officer | A | — | — |
| 2026-04-03 | Yuri Maricich | Chief Medical Officer | A | — | — |
| 2026-04-03 | Michael F MacLean | Director | A | — | — |
| 2026-04-03 | Daniel Tardiff | Chief Scientific Officer | A | — | — |
| 2025-12-22 | Kelly Gold | Chief Financial Officer | A | — | — |
| 2025-12-22 | Josh Mandel-Brehm | Chief Executive Officer | A | — | — |
| 2025-12-22 | Yuri Maricich | Chief Medical Officer | A | — | — |
| 2025-12-22 | Daniel Tardiff | Chief Scientific Officer | A | — | — |
| 2025-09-15 | Andrew J. Schwab | Director | A | — | — |
| 2025-09-15 | 5AM Ventures VI, L.P. | 10%+ Owner | Buy | — | — |
| 2025-09-11 | Kelly Gold | Chief Financial Officer | Buy | — | — |
| 2025-09-11 | Amir Nashat | Director | Buy | — | — |
| 2025-09-11 | Josh Mandel-Brehm | Chief Executive Officer | Buy | — | — |
| 2025-09-11 | Richard A Young | Director | Buy | — | — |
| 2025-09-11 | Yuri Maricich | Chief Medical Officer | Buy | — | — |
| 2025-09-11 | Brian Chee | 10%+ Owner | Buy | — | — |
| 2025-06-27 | Paula Ragan | Director | A | — | — |
| 2025-06-27 | Steven H Holtzman | Director | A | — | — |
| 2025-06-27 | James P Boylan | Director | A | — | — |
| 2025-06-27 | Ravi I. Thadhani | Director | A | — | — |
| 2025-06-27 | Andrew J. Schwab | Director | A | — | — |
| 2025-06-27 | Amir Nashat | Director | A | — | — |
| 2025-06-27 | Richard A Young | Director | A | — | — |
| 2025-06-27 | Michael J Higgins | Director | A | — | — |
| 2025-04-03 | Yuri Maricich | Chief Medical Officer | A | — | — |
| 2025-04-03 | David Bumcrot | Chief Scientific Officer | A | — | — |
| 2025-04-03 | Kelly Gold | Chief Financial Officer | A | — | — |
| 2025-04-03 | Josh Mandel-Brehm | Chief Executive Officer | A | — | — |
| 2025-03-19 | Murray Stewart | Director | A | — | — |
| 2025-03-19 | DOUGLAS E WILLIAMS | Director | A | — | — |
| 2024-10-22 | Polaris Management Co. VII, L.L.C. | 10%+ Owner | MIXED | — | — |
| 2024-10-17 | Enavate Sciences GP, LLC | 10%+ Owner | MIXED | — | — |
| 2024-10-17 | Michael P. Rubin | 10%+ Owner | MIXED | — | — |
| 2024-10-17 | AH Equity Partners Bio IV, L.L.C. | 10%+ Owner | MIXED | — | — |
| 2024-10-15 | Josh Mandel-Brehm | Chief Executive Officer | C | — | — |
| 2024-10-15 | Steven H Holtzman | Director | C | — | — |
| 2024-10-15 | Richard A Young | Director | C | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,941,176 | — |
| — | 10%+ Owner | 2,422,166 | — |
| — | 10%+ Owner | 1,579,885 | — |
| — | 10%+ Owner | 909,090 | — |
| — | 10%+ Owner | 763,636 | — |
| — | Director | 302,770 | — |
| — | 10%+ Owner | 302,770 | — |
| — | Chief Executive Officer | 284,968 | — |
| — | Director | 197,661 | — |
| — | Director | 186,388 | — |
| — | 10%+ Owner | 112,193 | — |
| — | 10%+ Owner | 112,193 | — |
| — | Director | 108,946 | — |
| — | Chief Financial Officer | 74,428 | — |
| — | Chief Medical Officer | 12,611 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CAMP quote page; the site-wide leaderboard is on the insider transactions hub.